Methods to minimize the risks of Creutzfeldt-Jakob disease transmission by surgical procedures: Where to set the standard?

Clinical Infectious Diseases

Volumn 43, Issue 6, 2006, Pages 757-764

  Sutton, J Mark ^a   Dickinson, Joanne ^a   Walker, James T ^a   Raven, Neil D H ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD TRANSFUSION; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; EARLY DIAGNOSIS; HUMAN; NONHUMAN; ORGAN TRANSPLANTATION; PREVALENCE; PRION; PRION DISEASE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; SURGICAL INSTRUMENT; SURGICAL RISK;

BLOOD TRANSFUSION; CREUTZFELDT-JAKOB SYNDROME; DECONTAMINATION; DISEASE OUTBREAKS; HUMANS; POSTOPERATIVE COMPLICATIONS; PRIONS; RISK ASSESSMENT; RISK FACTORS; SURGICAL INSTRUMENTS;

EID: 33748305582     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/507030     Document Type: Review

References (37)

1. Chesebro B. Introduction to the transmissible spongiform encephalopathies or prion diseases. Br Med Bull 2003; 66:1-20.
2. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. Updated projections of future vCJD deaths in the UK. BMC Infect Dis 2003; 3:4.
3. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527-9.
4. Ironside JW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapies. Haemophilia 2006; 12(Suppl 1):8-15.
5. Bishop MT, Hart P, Aitchison L, et al. Predicting susceptibility and incubation time of human-to-human transmission of vCJD. Lancet Neurol 2006; 5:393-8.
6. Hilton DA, Ghani AC, Conyers L, et al. Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 2004; 203:733-9.
7. Wadsworth JD, Asante EA, Desbruslais M, et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 2004; 306:1793-6.
8. Risk assessment for vCJD and dentistry. Economics and Operational Research Division. Available at: http://www.dh.gov.uk/Policy AndGuidance/HealthAndSocialCareTopics/CJD/CJDAssociatedPublica tions/fs/en?CONTENT_ID=4120472&chk=SGTAFJ. Accessed 9 August 2006.
9. Will RG. Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 2003; 66:255-65.
10. New case of variant CJD associated with blood transfusion. Available at: http://www.hpa.org.uk/hpa/news/articles/press_releases/2006/0602 09_cjd.htm. Accessed 9 August 2006.
11. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417-21.
12. Ludlam CA, Turner ML. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products. Br J Haematol 2006; 132:13-24.
13. Brown P, Gibbs CJ Jr, Rodgers-Johnson P, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994; 35:513-29.
14. Bruce ME, McConnell I, Will RG, Ironside JW. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 2001; 358:208-9.
15. Head MW, Northcott V, Rennison K, et al. Prion protein accumulation in eyes of patients with sporadic and variant Creutzfeldt-Jakob disease. Invest Ophthalmol Vis Sci 2003; 44:342-6.
16. Head MW, Ritchie D, McLoughlin V, Ironside JW. Investigation of PrPres in dental tissues in variant CJD. Br Dent J 2003; 195:339-43.
17. Head MW, Ritchie D, Smith N, et al. Peripheral tissue involvement in sporadic, iatrogenic, and variant Creutzfeldt-Jakob disease: an immunohistochemical, quantitative, and biochemical study. Am J Pathol 2004; 164:143-53.
18. Joiner S, Linehan JM, Brandner S, Wadsworth JD, Collinge J. High levels of disease related prion protein in the ileum in variant Creutzfeldt-Jakob disease. Gut 2005; 54:1506-8.
19. Peden AH, Ritchie DL, Head MW, Ironside JW. Detection and localization of PrPSc in the skeletal muscle of patients with variant, iatrogenic, and sporadic forms of Creutzfeldt-Jakob disease. Am J Pathol 2006; 168:927-35.
20. Wadsworth JD, Joiner S, Hill AF, et al. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001; 358:171-80.
21. Assessing the risk of vCJD transmission via surgery: an interim review. Available at: http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsPolicyAndGuidance/PublicationsPolicyAnd GuidaneeArticle/fs/en? CONTENT_ID=4113541&chk=Aklzhj. Accessed 9 August 2006.
22. Rutala WA, Weber DJ. Creutzfeldt-Jakob disease: recommendations for disinfection and sterilization. Clin Infect Dis 2001; 32:1348-56.
23. Risk Assessment for vCJD and dentistry: economics and operational research division. 2003. Available at: http://www.dh.gov.uk/ PublicationsAndStatistics/Publications/PublicationsPolicyAndGuid ance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4084662&chk= twiXsY. Accessed 23 January 2006.
24. Ingrosso L, Pisani F, Pocchiari M. Transmission of the 263K scrapie strain by the dental route. J Gen Virol 1999; 80:3043-7.
25. Heikenwalder M, Zeller N, Seeger H, et al. Chronic lymphocytic inflammation specifies the organ tropism of prions. Science 2005; 307:1107-10.
26. Fichet G, Comoy E, Duval C, et al. Novel methods for disinfection of prion-contaminated medical devices. Lancet 2004; 364:521-6.
27. Yan ZX, Stitz L, Heeg P, Pfaff E, Roth K. Infectivity of prion protein bound to stainless steel wires: a model for testing decontamination procedures for transmissible spongiform encephalopathies. Infect Control Hosp Epidemiol 2004; 25:280-3.
28. Zobeley E, Flechsig E, Cozzio A, Enari M, Weissmann C. Infectivity of scrapie prions bound to a stainless steel surface. Mol Med 1999; 5:240-3.
29. Jackson GS, McKintosh E, Flechsig E, et al. An enzyme-detergent method for effective prion decontamination of surgical steel. J Gen Virol 2005; 86:869-78.
30. Peretz D, Supattapone S, Giles K, et al. Inactivation of prions by acidic sodium dodecyl sulfate. J Virol 2006; 80:322-31.
31. McLeod AH, Murdoch H, Dickinson J, et al. Proteolytic inactivation of the bovine spongiform encephalopathy agent. Biochem Biophys Res Commun 2004; 317:1165-70.
32. Baxter HC, Campbell GA, Whittaker AG, et al. Elimination of transmissible spongiform encephalopathy infectivity and decontamination of surgical instruments by using radio-frequency gas-plasma treatment. J Gen Virol 2005; 86:2393-9.
33. Taylor DM. Resistance of transmissible spongiform encephalopathy agents to decontamination. Contrib Microbiol 2004; 11:136-45.
34. Questions and answers: Creutzfeldt-Jakob disease infection-control practices. Available at: http://www.cdc.gov/ncidod/dvrd/cjd/ infection_control_cjd.htm#reprocessed. Accessed 9 August 2006.
35. World Health Organization infection control guidelines for transmissible spongiform encephalopathies. Available at: http://www.who.int/csr/resources/ publications/bse/whocdscsraph2003.pdf and http://www .who.int/csr/resources/ publications/bse/whocdscsraph2003.pdf. Accessed 9 August 2006.
36. Transmissible spongiform encephalopathy agents: safe working and the prevention of infection. Available at: http://www.advisorybodies.doh.gov.uk/ acdp/tseguidance/ Accessed 9 August 2006.
37. Sehulster LM. Prion inactivation and medical instrument reprocessing: challenges facing healthcare facilities. Infect Control Hosp Epidemiol 2004; 25:276-9.